The next genera+on of nature - OTCQX: CANSF - Willow Biosciences
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
The next genera+on
of nature.
July 2021 TSX: WLLW
willowbio.com OTCQX: CANSF
Willow’s technologies & capabilities
WILLOW IS FOCUSED ON DEVELOPING COMPLETE PROCESS SOLUTIONS THAT COMBINE STATE-OF-THE-
ART TECHNOLOGIES FOR STRAIN, FERMENTATION & DOWNSTREAM PROCESS DEVELOPMENT
P R O C E S S D E V E L O P M E N T (USP & DSP)
(Undisclosed DSP Technology Partner)
SCALE UP (other CMOs)
INPUT
Willow’s Rapid Strain Engineering
bench scale TESTING & RELEASE
Technologies combine:
ü Proprietary plant genomes
ü Machine learning-guided OUTPUT
pathway optimization
performance Ingredients:
ü Enzyme evolution platform strain
pilot & ü Consumer care
ü Genome-wide editing
production ü Flavor & fragrance
technologies
ü Food & beverage
ü HTP screening capabilities
ü Pharma
lab strain
P A G E 2
Our commitment to managing sustainability
OUR FERMENTATION PROCESS ENABLES RESOURCE EFFICIENT AND SUSTAINABLE GROWTH
Key environmental performance comparison
Willow’s biosynthesis process vs plant-based cannabinoid production1
Other Willow business priorities:
Relative CO2 emissions per Relative water requirements Kilograms biomass per
kilogram CBD produced2 per kilogram CBD produced3 kilogram CBD produced4
600 400 200
527x PEOPLE
333x
500
150 150
300
142
400
≠ PARTNERS
300 100
200
200
155x
100
100 58x 58x SAFETY
44x
1x 1x
0.1
0 0
0
fermentation warehouse greenhouse outdoor fermentation warehouse greenhouse outdoor fermentation warehouse greenhouse outdoor
PRODUCT
QUALITY
Land use:
Fermentation and indoor cultivation facilities can be located on property with sufficient access to labour and utilities, avoiding the need to devote arable
land to non-food production. The uncontrolled environment of outdoor cannabis operations can lead to heavy pest and weed pressure, leading to crop
failures and wasted resources.
1. Assumes average dry flower yield of 10% CBDa (w/w) or CBDa production of 5 g/L in 100,000L fermentation facility.
2. Posterity Group (2019) Report of Findings: Greenhouse Energy Profile Study; & Willow management estimates. Emissions calculated using Government of Alberta (2019) Carbon offset emission factors handbook. Version 2.0
3. Upland Agriculture Consulting (2019) Commercial cannabis production in British Columbia: best available control technologies and regulatory oversight of environmental considerations; & Willow management estimates
4. Willow management estimates
P A G E 3
Our ESG committee
STRONG FRAMEWORK IN PLACE TO MONITOR SUSTAINABILITY METRICS
BOARD MEMBER
Compensation & Governance Committee Chair
Our commitment to
managing sustainability TRAVIS DOUPE
CFO
• Establish ESG governance structure
with board level oversight (2021)
• Conduct materiality assessment to
identify and prioritize key topics for
our business and to our
stakeholders (2021)
customer needs investor relations environmental governance & social
• Develop a robust ESG strategy and SIMON TROY MARK KIM
roadmap (2021) HICKLING TALKKARI SMOLENSKI MARTYN
Senior VP Business VP Corporate Senior Director General
• Disclose ESG performance (2022) Development Development Manufacturing Operations Counsel
INPUTS OUTPUTS
P A G E 4
Willow’s cannabinoid production process
COMBINING STRAIN ENGINEERING WITH PROCESS DEVELOPMENT TO DEVELOP BIOBASED ROUTES TO CANNABINOIDS
Cannabinoid OH
Controlled input: decarboxylation
• Basic nutrients (purity & potency
• Carbon source feed >99%) HO
• Substrate feed
• 4-5-day process
Chemical
e.g., cannabigerol, CBG
Decarboxylation
Performance
Strain Cannabinoid
isolation from OH
fermentation Cannabinoid COOH
(purity & potency
broth
>99%)
HO
Fermentation Primary Isolation
Purification e.g., cannabigerolic acid, CBGA
Upstream Process (USP) Downstream Process (DSP)
BENEFITS OF BIOSYNTHESIS
• Yeast produces only target cannabinoid with no interfering by-products
• DSP typically requires no chromatography to achieve high purity
Formerly AMRI
• Only minor process changes for other cannabinoids
• Platform easily extends to production of other cannabinoids and terpenes
P A G E 5
Demonstrated ability to commercialize compounds
WE HAVE LAUNCHED OUR FIRST COMPOUND AND HAVE A ROBUST PIPELINE OF FUTURE HIGH VALUE MOLECULES
compound potential addressable markets lab strain optimized strain pilot ready scale production launch
CANNABINOIDS
CBG/CBGA Cosmetics, food & beverage Now
THC/THCA Food & beverage, pharma
CBD/CBDA Cosmetics, food & beverage, pharma
CBN/CBNA Sedative & sleep aid
CBGV/CBGVA Cosmetics, food & beverage, pharma
THCV/THCVA Appetite suppressant, pharma
CBDV/CBDVA Cosmetics, health & wellness, pharma
Undisclosed Cosmetics, food & beverage
Undisclosed Food & beverage
OTHER CLASSES
Terpenes Cannabis additives, flavors & fragrances
In just over two years, we have gone from proof of concept in the lab to commercially producing our first cannabinoid, CBG. Based on this
success and the platform technology our next cannabinoids will take less time and capital
P A G E 6
Technology in action: from lab to production
PROGRAM 1 IS THE BASIS FOR THE ENTIRE PLATFORM
Development of Commercially Relevant Strains & Process SCALING AND REFINING PROCESS
100
90 CBG – Currently at production scale
80
70
THC – Currently at bench scale
(% COMPLETE)
60
50
CBD – Currently at lab scale
40
30
20 Varins – Currently at lab scale
10
0
Non-Cannabinoid – Currently at
screening stage
2020 2021 2022 2023 2024
P A G E 7
CBG – A health and wellness molecule
THE NEXT BIGGEST CANNABINOID FOR HEALTH AND WELLNESS
• In the plant, cannabigerol (CBG) is converted to other cannabinoids such as THC and CBD, hence the
CBGA nickname “Mother of All Cannabinoids”
master acidic
precursor
‒ CBG naturally occurs at such small concentrations that it is challenging to manufacture economically with high purity levels
‒ Non-psychoactive properties allow for a favorable global regulatory view (not on the U.S. Controlled Substances Act)
• Of the more then 450 chemicals identified in the cannabis plant, CBG is one of the most compelling from
the perspective of human health
CBDA THCA • CBG has the potential to be as impactful to the recreational, health and wellness landscape as CBD has
acidic precursor
become
acidic precursor
CBG ‒ As an anti-inflammatory, CBG has been shown to outperform CBD under certain conditions
neutral
• Global CBD market estimated at $2.7 billion in 2021 and forecast to grow at CAGR of 51% from 2021 to 20301.
CBD THC CBG’s ability to be a substitute or even superior molecule, implies large potential addressable market
neutral neutral
1
SOURCE: Quince Market Insights June 1, 2021
Willow’s Ultra-Pure CBG Health & Wellness Products
(Input) (Output)
Characteristics of Willow’s CBG make
it ideal for product integration:
• Anti-microbial >$1 trillion
• >99% purity
• Consistent batches CBG global market
• Anti-oxidant
• Odorless
• Anti-inflammatory • Powder form
= GRAS designation required (Willow pursuing)
P A G E 8
CBG – a potent skincare active ingredient
Global cosmetics market was valued at $380 billion in 2019 and projected to reach $464
billion by 20271, with the largest portion being skin and sun care products
Anti-bacterial
• Prevents bacterial growth in
skin, including, C. acnes
Anti-aging
• Stimulates Sebocyte gland in
skin which releases moisture
Anti-inflammatory
• Increases collagen production • Suppresses inflammation in skin
cannabigerol induced by bacteria, UV and other
(CBG) environmental factors
1. Source: Feb 2021 industry report by Allied Market Research
March 2021 April 2021 May 2021 June 2021 2021+
first commercial production completed a series of studies the European Commission adds CBG to signed multi-year supply continue to sign new
run of Willow CBG demonstrating the safety and anti- the EU’s cosmetic ingredients database agreement with Cellular Goods partnerships and potentially
inflammatory, anti-aging, and (named "CosIng"), approving the bring own skin care products to
antimicrobial properties of Willow compound as safe for use in personal market
CBG on human skin care and cosmetics products
P A G E 9
Growing portfolio of cannabinoids
WILLOW’S PRODUCTION SUCCESS WITH CBG IS TRANSFERRABLE TO OTHER CANNABINOIDS
CBG THC CBD CBGV THCV CBDV CBN
cannabigerol tetrahydrocannabinol cannabidiol cannabigervarin tetrahydrocannabivarin cannabidivari cannabinoid
• Antimicrobial • Pain • Inflammation • Inflammation • Appetite • Brain and • Sleep aid or
• Antioxidant effects • Sleep aid • Recovery • Recovery suppressant peripheral nervous sedative
• Digestion and • Stimulates • Pain • Brain system • Regulate immune
• Pain
intestines appetite • Brain and central • Bone growth • Nausea system
• Brain and central
• Inflammation • Muscle relaxant nervous system nervous system • Metabolism • Seizures • Inflammation
• Nausea • Cardiovascular • Cardiovascular • Immunity
• Pain system system
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by Health Canada and the US Food
and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
• Growing knowledge and acceptance of cannabinoid benefits
‒ ~50 cannabinoid-based treatments currently in clinical trials
• Requires consistent, high-quality ingredients
minor cannabinoid major cannabinoid
• Early-stage potential for growing range of cannabinoids for pain, anxiety,
obesity, brain disorders, cancer treatments and more
P A G E 1 0Global acceptance of cannabinoids presents large addressable market
Potential global CPG market for biosynthetically produced cannabinoids estimated at $8b in 2025 and $27b in 20301
1. Source: Raymond James, Ltd. (June 23, 2020 report)
P A G E 1 1Willow’s best in class management & technical team
WILLOW’S TEAM HAS THE NECESSARY EXPERIENCE TO ACHIEVE SUCCESS
Proven scientific team
Vancouver, BC • Plant Sciences R&D
• Extensive industrial biotech expertise and essential capabilities for building
• Quality Assurance
successful cannabinoid production strains & processes: gene discovery, high
• Quality Control
throughout strain optimization and process development
• Total headcount 55
o Research & development
o CMC group managing CMO network
o Quality group, including QC testing & release
o Product development & business development teams
• Strain Engineering
Mountain View, CA
• Fermentation R&D
• Commercial Operations
Successful business team
• Management team cofounded five companies, all of which successfully sold for
> $4 billion in aggregate
o Raised more than $1 billion in equity and debt
• Diverse board of directors cofounded seven companies, all of which
successfully sold for > $8 billion in aggregate
• Strong focus on corporate governance – experienced, knowledgeable and
diverse board, with all independent directors, other than CEO
P P
AAGG
E E 162Strong financial position
STRATEGIC INDUSTRY AND FINANCIAL PARTNERS POSITION WILLOW FOR A STRONG FUTURE PERFORMANCE
In February 2021, raised $28.75 million via prospectus offering to support
Willow share capitalization (TSX: WLLW) – As of March 31, 2021
research, strain development, scale up and commercial launch
Basic shares outstanding (mm) 123.5
$77.3 million raised to date with management and board investing
Employee options 7.7
more then $8 million personally into Willow
Warrants (mm)2 16.7
March 31st, 2021 cash position equals $46.5 million with no debt
Performance warrants (mm)3 12.1
Strong insider ownership at 31% Fully diluted shares outstanding (mm) 159.9
Aligned with shareholders – Insider's performance incentive achieved
1. Weighted average strike price of $1.40
when WLLW has 20 day VWAP of $3.50 per share 2. 15.0mm issued in the April 2019 financing to strategic investors, management and board with a 5 year term.
These warrants have a strike price of $0.88 per share. 1.0mm broker warrants issued in connection with the
February 2021 financing with a 2 year term, strike price of $2.15 per warrant and the ability for Willow to force
Funded to commercialize production convert at a 20 day VWAP of $3.05. Remaining warrants have a weighted average strike price of $8.01 per share.
3. Additional warrants issued if the 20 day VWAP exceeds a share price of $3.50 per share and Willow is listed on
the TSX (or equivalent exchange).c
Moved to TSX in Dec 2019 (TSX: WLLW)
Trade on OTCQX® Best Market (OTCQX: CANSF)
P A G E 1 3Strong foundation built for future growth
2019 2020 2021 2021+
• Go public transaction via • Commenced scale-up of CBG
• Added THC to portfolio of cannabinoids, to be
RTO raised $37 million with with AMRI Continue to sign
sold in Canada (or other fully legal •
Tuatara Capital jurisdictions) up CBG related
committing $20 million to
financing supply agreements
• Raised $28.75 million via prospectus offering
• 500-liter production pilot for CBG
kicked off six months ahead of
Completed first commercial scale • Commercialize
•
schedule fermentation run of CBG additional
• Added multiple new cannabinoids
cannabinoids
• Announced ground-breaking scientific data for
• Started build out of the to portfolio (CBD, CBGV, THCV, CBG on human skin, shown to be anti-aging,
CDBV) • Complete GRAS
state-of-the-art strain antimicrobial, anti-inflammatory
engineering lab in work for CBG
Mountain View, CA • Produced >99% pure CBG from
• Added to major cannabis ETF's (TSX: HMMJ, (anticipated H1
pilot, samples distributed to NYSE: THCX) 2022) enabling
• Commenced trading on prospective clients
food & beverage
OTC in U.S. (OTCQB: CANSF) • Presented CBG data on human skin at Society
• Raised $18 million via prospectus for Investigative Dermatology conference
consumer
• Uplisted to the TSX Main offering to advance R&D and products
board (TSX: WLLW) commercialization efforts Announced multiyear supply agreement for
•
CBG with Cellular Goods • Start to work on
• Announced it had selected CMO
to commence commercialization
other classes of
of CBG in Q1 2021, six months compounds
ahead of schedule
• Added CBN to portfolio of cannabinoids beyond
cannabinoids
• Commenced commitment to manage
sustainability with formation of ESG committee
P A G E 1 4appendix
Leadership
management technical & sales
Trevor Peters Chris Savile, PHD Travis Doupe, CPA,CA Mathias Schuetz, PhD Trish Choudhary, PhD Troy Talkkari, CFA Simon Hickling, PhD
CEO, President & VP Research & VP Corporate SVP Business
COO CFO VP Plant Science
Director Development Development Development
Experienced executive having Over 15 years in science, CPA,CA with over 18 years’ Adjunct Professor Dept of
business development, and Botany UBC, researcher and Over 15 years’ experience 25 years’ experience in
co-founded four start-up experience as a financial 15 years' experience in R&D and
commercial operations roles plant molecular biologist in the finance industry and production and international
companies in the past 15 executive, principally in start-
with extensive expertise in lab operations optimizing was most recently a business development in the
up companies
plant genetics and cannabis biological processes for Director of Institutional pharmaceutical and biotech
Instrumental in seven public Highly experienced scientist technology industrial biotech and food Equity Sales at GMP industry, having previously
and private start-up focused on the FirstEnergy held roles at DSM, Codexis and
companies in the energy CFO several publicly-listing Over 14 years’ research applications
development, scale-up and companies including most experience and author of PharmaZell
industry over the past 20 years Was part of 66 M&A
commercialization of recently, Suroco Energy Inc., a many peer-reviewed Highly experienced in
biobased manufacturing Canadian based, TSXV-listed publications in prestigious transactions totalling over Proven track record of
developing high throughput $22 billion in value developing mutually
Raised over $1 billion in equity processes energy company with plant science journals
and debt financings at various microbial strain engineering successful commercial
operations in Colombia and Numerous citations and Was part of 833 financings,
stages of corporate R&D and operational leader platforms for production of relationships to meet client’s
prior Milagro Energy (TSX) awards for research including 279 as the lead
development on several programs that led commercially relevant specific product needs, with a
excellence dealer, totalling over $131
to commercial focus on cutting-edge
compounds billion of capital raised
Successful transactions manufacturing processes Served in positions of PhD in 2009 at Simon Fraser technologies in highly
totaling over $4 billion on sale increasing importance at University regulated markets
Proven track record of CFA designation and
Sherritt Oil & Gas, including Bachelor of Commerce in
PhD in 2005 at McGill Finance Manager & Controller enabling innovative Received his B.Sc. (Hons) from
Extensive intellectual property University technologies from initial Finance from the University Sheffield Hallam University
and patent prosecution and Controller of NAL of British Columbia
Resources (TSX) concept through development (U.K.) and his Ph.D. from the
background in the energy University of Bath (U.K.)
technology sector by building and leading high
Roles with PwC in Calgary, performing, multidisciplinary
Alberta and Havana, Cuba teams.
PhD in 2008 from Macquarie
University, NSW, Australia
P A G E 1 6Leadership
diverse board of directors
Peter Seufer-Wasserthal, Donald Archibald Fotis Kalantzis, PhD Al Foreman Sadiq Lalani Barbara Munroe
PhD Independent Director Independent Director Director Independent Director Independent Director
Chairman
Independent businessman with 25 years experience in oil and gas 25 years’ experience as Chief
25 years of experience in the Partner and Chief Investment More than 25 years of experience as
significant senior executive and exploration and development. Financial Officer of publicly-
technology and biotechnology board experience for numerous Currently CEO and President of Officer at Tuatara Capital a lawyer and executive in diverse
sector listed issuers, including current
public and private companies Spartan Delta Corp. Vice President & CFO at Kelt industries. Current Chair of the
Previously, Managing Director at Exploration Ltd. Board of Crescent Point Energy Corp
Currently Chief Commercial Co-founder and senior executive JP Morgan in the Financial
Officer of Sestina Bio, LLC Director of Spartan Delta Corp.
Previous director and audit of several public companies Sponsors Group and Private C-Suite Energy Executive Has served as an executive in
committee member of including Spartan Energy Corp., Equity Fund Services Business Awards CFO of the Year several customer-centric and
Previously Chief Commercial publicly-traded Spartan Energy Spartan Oil Corp. and Spartan
Officer of Origenis GmbH diverse industries, as EVP, Corporate
Corp. and Spartan Oil Corp. Exploration Ltd.
Began his career at Citigroup, Services and General Counsel for
Previously VP, Business and has held executive roles at WestJet Airlines Ltd., the Assistant
Development for Intrexon Previously President of Cypress Holds an M.SC from the University
several companies General Counsel, Upstream at
Corporation, responsible for Energy Corp., Chairman & CEO of Saskatchewan and a PhD from
of Cyries Energy Inc. and the University of Alberta Imperial Oil Ltd., and the Senior Vice
business development in Europe
and Asia for four years President & CEO of Cequel President, Legal/IP & General
Holds a B.S. Finance (University of
Energy Inc. Counsel, Corporate Secretary for
Published and presented Connecticut) and a dual J.D./MBA
A member of the Institute of numerous papers in international SMART Technologies Inc.
(Arizona State University)
Corporate Directors and holds Holds a B.Comm (University of journals and conferences
the ICD.D designation
Alberta) and MBA (University of A member of the Institute of
Western Ontario) Corporate Directors and has
Received a Ph.D. (Technical extensive corporate governance
University of Graz)
experience
Holds a Bachelor of Commerce,
Finance degree and a Bachelor of
Laws degree, both from the
University of Calgary. Admitted to
the Law Society of Alberta in 1991
and holds the ICD.D designation
P A G E 1 7Disclaimer
Forward Looking Statements. Certain information included in this presentation viability, safety, efficacy, dosing and social acceptance of cannabinoids; the While such information is believed to be reliable for the purpose used herein,
constitutes forward-looking information under applicable securities legislation. capital markets and the general economy; changes to cannabis laws and Willow does not assume any responsibility for the accuracy of such information.
Forward-looking information typically contains statements with words such as regulations in Canada, the United States and Europe; the legalization of the use None of the sources cited in this presentation have consented to the inclusion of
"will", "anticipate", "believe", "expect", "plan", "intend", "estimate", "propose" or of cannabis for medical and/or adult use in jurisdictions outside of Canada; any data from their reports, nor has Willow sought their consent.
similar words suggesting future outcomes or statements regarding an outlook. and applicable laws not changing in a manner that is unfavorable to the
Forward-looking information in this presentation includes, but is not limited to, Company. FOFI Disclosure. This presentation contains future-oriented financial information
statements relating to: the business, strategies, expectations, planned and financial outlook information (collectively, "FOFI") concerning Willow's
operations and future actions of Willow Biosciences Inc. ("Willow" or the Although Willow believes that the expectations and assumptions on which the financial position, liquidity, available funds, ability to fund commercial
"Company"), including research and development programs at the facilities forward-looking statements are based are reasonable, undue reliance should production, market capitalization and components thereof, as well as FOFI
located in British Columbia and California; the Company's ability to not be placed on the forward-looking statements because Willow can give no concerning the estimated size of the global biosynthetic cannabinoid market
commercially biosynthesize and create proprietary genomes; Willow's assurance that they will prove to be correct. Since forward-looking statements (including the compound annual growth rate of the cannabinoid market), all of
milestone projections, including the timing of commercialization of the various address future events and conditions, by their very nature they involve inherent which are subject to the same assumptions, risk factors, limitations and
cannabinoids in its product portfolio; expected therapeutic benefits of Willow's risks and uncertainties. Actual results could differ materially from those currently qualifications as set forth in the above paragraphs. FOFI contained in this
portfolio cannabinoids, including CBG; expected benefits and cost-savings anticipated due to a number of factors and risks. These include, but are not presentation was approved by management as of the date of this presentation
resulting from commercial-scale production via the Company's fermentation limited to, permits, licenses and regulatory and third party approvals not being and was provided for the purpose of providing further information about
manufacturing platform, including manufacturing performance estimates and obtained in the manner or timing anticipated by the Company; the ability to Willow's anticipated future business operations. Willow disclaims any intention
forecasts; the development of Willow's intellectual property portfolio; the implement corporate strategies; failure of counter-parties to perform or obligation to update or revise any FOFI contained in this presentation,
arrangements under, and potential benefits of, its strategic partnerships; contractual obligations; the state of domestic and international capital whether as a result of new information, future events or otherwise, unless
discussions with cosmetics and consumer-packaged goods entities, markets; risks associated with the cannabis and cannabinoid industries in required pursuant to applicable law. Readers are cautioned that the FOFI
manufacturing partners and other key stakeholders; the performance of the general; infringement on intellectual property; failure to benefit from contained in this presentation should not be used for purposes other than for
Company's business and operations; the financial strength of the Company; the partnerships or successfully integrate acquisitions; actions and initiatives of which it is disclosed herein.
ability of the Company to fund its business plan using cash on hand and federal and provincial governments and changes to government policies and
the execution and impact of these actions, initiatives and policies; No Offer. This presentation does not constitute an offer to sell or solicitation of
existing resources; the size of the biosynthetic cannabinoid market, including
import/export and research restrictions for cannabinoid-based operations; the an offer to buy any securities of the Company. The sole purpose of this
potential demand for Willow's cannabinoids from the pharmaceutical, presentation, in paper or electronic form, is strictly for information purposes.
cosmetics and consumer packaged goods industries; Willow's expected size of the medical-use and adult-use cannabis market; competition from other
customer-base and potential addressable markets; the competitive conditions industry participants; and other factors more fully described from time to time
U.S. Registration. This presentation is not an offer of any securities of the
of the industry in which the Company operates and the competitive in the reports and filings made by the Company with securities regulatory
Company for sale in the United States. The Company's securities have not been
advantages of the Company; the performance of the current science team, authorities. Please refer to the Company's Annual Information Form and the registered under the U.S. Securities Act of 1933, as amended, and may not be
management and board and the ability to find other qualified personnel with Management's Discussion and Analysis for additional risk factors relating to
offered or sold in the United States absent registration or an exemption from
operational experience; the Company's ESG efforts and objectives; and the Willow, which can be accessed either on Willow's website at www.willowbio.com registration. This presentation shall not constitute an offer to sell or the
Company's future product offerings, including the development of other or under the Company's profile on www.sedar.com.
solicitation of an offer to buy nor shall there be any sale of the securities in any
cannabinoids in Willow's product portfolio and the future production levels, Readers are cautioned that the assumptions used in the preparation of state in which such offer, solicitation or sale would be unlawful.
quality, consistency and costs thereof.
forward-looking information, although considered reasonable at the time of
The forward-looking statements contained in this presentation are based on preparation, may prove to be imprecise. Willow's actual results, performance or
certain key expectations and assumptions made by Willow, including achievement could differ materially from those expressed in, or implied by,
expectations and assumptions concerning: the future operations of, and these forward-looking statements and accordingly there can be no assurance
transactions completed by, the Company; the potential for strategic that such expectations will be realized and/or what benefits Willow will derive
partnerships to open new and larger markets (including non-pharmaceutical therefrom. The forward-looking information contained in this presentation is
markets); Willow's ability to generate higher quality cannabinoids at lower costs; made as of the date hereof and Willow undertakes no obligation to update or
cost synergies created by its strategic partnerships and the successful revise any forward-looking information, whether as a result of new information,
implementation thereof; the adequacy of current capital; the availability of and future events or otherwise, unless required by applicable securities laws. The
access to qualified personnel; the results of scientific research; the Company's forward-looking information contained in this presentation is expressly qualified
ability to protect its intellectual property; the expected growth in the by this cautionary statement.
biosynthetic cannabinoid market, including demand for cultured cannabinoids Third-Party Information. Certain information contained herein has been
from the pharmaceutical, cosmetics and consumer packaged goods
obtained from published sources prepared by independent industry analysts
industries; expectations regarding the regulatory framework for cultured
and third-party sources (including industry publications, surveys and forecasts),
cannabinoids; changes in prices and costs of inputs; the medical benefits,
P A G E 1 8THANK YOU Trevor Peters CEO, President & Director Troy Talkkari, CFA Vice President, Corporate Development T: (403) 618-1117 E: info@willowbio.com
You can also read
